Clinical trials: Dupilumab
Dermatitis, Atopic
Results in Real Clinical Practice of Treatment of Moderate-severe Atopic Dermatitis
The purpose of this study is to determine the efficacy results in terms of percentage improvement of the Eczema Area and Severity Index (EASI) as well as on the scale Patient Global Assessment (PGA) throughout the follow-up of…
- Trial name
- Dermatitis (NCT05078294)
- Where
- 7 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Pathophysiology
Immunological Mechanisms Underlying Mucosal IgE Responses
Background / rationale: Type 2 inflammation is driving several chronic diseases in the airway. On one hand allergic rhinitis (AR) and allergic asthma (AA) are driven by allergen expose, while on the other hand eosinophilic Type 2…
- Trial name
- NCT06234761
- Testing
- Dupilumab
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- University Hospital, Ghent
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps
The investigators are studying adults who have chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, and who are undergoing Endoscopic Sinus Surgery (ESS).
- Trial name
- NCT06556264
- Testing
- Dupilumab
- Volunteers
- 60 people
- Sponsor
- Dr. Andrew Thamboo, MD
Atopic Dermatitis
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT07399067
- Testing
- IBI3002, Dupilumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Major Depressive Disorder
Dupilumab in Major Depressive Disorder
This study aims primarily to test target engagement of dupilumab by assessing changes in peripheral immune markers following interleukin-4 receptor alpha (IL-4Rα) blockade in adults with major depressive disorder (MDD).
- Trial name
- NCT07908563
- Testing
- Dupilumab Injection
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered…
- Trial name
- RECLAIM (NCT06868212)
- Testing
- Remibrutinib, Dupilumab
- Where
- 121 sites in United States
- Volunteers
- 409 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Pain
Virtual Reality for Pain Management During Dupilumab Injection
The aim of this within-subject randomized study is to examine the efficacy of a VR immersive game for pain and anxiety management of children during the subcutaneous injection of dupilumab for moderate to severe atopic…
- Conditions
- Atopic Dermatitis, Pain, Anxiety
- Trial name
- VR-DERMA (NCT06182436)
- Testing
- Virtual Reality Distraction, Standard Treatment
- Where
- 2 sites in Canada
- Volunteers
- 98 people
- Sponsor
- St. Justine's Hospital
Severe Atopic Dermatitis (AD)
Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab
This study is researching an approved drug called dupilumab (called "study drug"). Dupilumab is approved in the United States for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe…
- Trial name
- BUILD-PEDS (NCT07187089)
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- Liberty AD (NCT03346434)
- Testing
- Dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Tralokinumab for Dupilumab Failures
24-week study of 20 atopic dermatitis patients who have been treated with dupilumab will receive Tralokinumab 600mg at week 0 followed by 300mg Q2W for 24 weeks.
- Trial name
- NCT06773455
- Testing
- tralokinumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Atopic Dermatitis
Dupilumab De-escalation in Pediatric Atopic Dermatitis
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD)…
- Trial name
- NCT06116526
- Testing
- Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University